A multi-center, randomized, controlled trial for Yinqiao Xiashi Formula/Xuanling Yinhuang Formula plus Angong Niuhuang Bolus in the treatment of adult viral encephalitis and meningitis

TCM early clinical treatment system and pre-plan study of acute infectious diseases - Optimization of diagnosis and treatment pre-plan and treatment plan for encephalitis and meningitis syndrome by integrated Chinese and western medicine.

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900023279

Enrollment

Unknown

Registered

2019-05-20

Start date

2019-06-01

Completion date

Unknown

Last updated

2019-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cases of viral encephalitis and meningitis

Interventions

Experimental group:(basic treatment + Yinqiao Xiashi Formula) or (Basic treatment + Xuanling Yinhuang Formula and Angong Niuhuang Bolus)

Control group:basic treatment

Eligibility

Sex/Gender

All

Age

14 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria for viral encephalitis and meningitis; 2. Meet the syndrome diagnosis of syndrome of disease involving 'weifen' and 'qifen' or syndrome of blazing heat in both 'qi' and nutrient phases; 3. Inpatient; 4. The course of disease is = 7 days; 5. Voluntary participation in this study, the patients or their guardian signed an informed consent form.

Exclusion criteria

Exclusion criteria: 1. Encephalitis and meningitis caused by non-viral infections; 2. Aged 65 years old; 3. Pregnant or lactating women; 4. Concomitant with other serious systemic diseases (such as cardiovascular and cerebrovascular diseases) and mentally ill patients; 5. Patients with intracranial space-occupying lesions; 6. Patients with severe complications such as septic shock and DIC; 7. Due to severe gastrointestinal bleeding, pancreatitis and other serious conditions, the patients who cannot be administered by the gastrointestinal tract after doctors judging; 8. Affecting data collection due to various factors; 9. Anti-HIV and / or syphilis antibody positive; 10. History of allergies to traditional Chinese medicine; 11. Participate in other clinical trials or research.

Design outcomes

Primary

Measure	Time frame
Cure rate;	—

Secondary

Measure	Time frame
Case fatality rate;GCS score;mRS score;Complication rate;Duration of body temperature returns to normal;Coma duration;Duration of convulsion relief;Antibiotic use rate;Incidence of gastrointestinal dysfunction;ICU occupancy rate;ICU occupancy duration;Duration of mechanical ventilation;Disability rate;TCM symptom score;Health economics evaluation;	—

Countries

China

Contacts

Public ContactLi Ang

Beijing Ditan Hospital, Capital Medical University

snowpine12@sina.com+86 15901033321

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026